Literature DB >> 28155015

Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications.

B A Cunha1,2, C B Cunha3,4, B Lam5, J Giuga5, J Chin5, V F Zafonte5, S Gerson5.   

Abstract

Nitrofurantoin remains a key oral antibiotic stewardship program (ASP) option in the treatment of acute uncomplicated cystitis (AUC) due to multi-drug resistant (MDR) Gram negative bacilli (GNB). However, there have been concerns regarding decreased nitrofurantoin efficacy with renal insufficiency. In our experience over the past three decades, nitrofurantoin has been safe and effective in treating AUC in hospitalized adults with renal insufficiency. Accordingly, we retrospectively reviewed our recent experience treating AUC in hospitalized adults with decreased renal function (CrCl < 60 ml/min) with nitrofurantoin. Excluded were complicated urinary tract infections. Urinary isolated susceptibility testing was done by micro broth dilution (MBD). Treatment duration was 5-7 days. Cure was defined as eradication of the uropathogen and failure was defined as minimal/no decrease in urine colony counts. Of 26 evaluable patients with renal insufficiency (CrCl < 60 ml/min), nitrofurantoin eradicated the uropathogen in 18/26 (69%) of patients, and failed in 8/26 (31%). Of the eight failures, five were due to intrinsically resistant uropathogens, e.g., Proteus sp., and one failure was related to an alkaline urine. Of the treatment failures, only two were due to renal insufficiency, i.e., CrCl < 30 ml/min. Since there are few oral antibiotics available to treat AUC due to MDR GNB uropathogens, these results have important ASP implications. Currently, nitfurantoin is not recommended if CrCl < 60 ml/min. In our experience, used appropriately against susceptible uropathogens, nitrofurantoin was highly effective in nearly all patients with CrCl = 30-60 ml/min., and only failed in two patients due to renal insufficiency (CrCl < 30 ml/ml).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28155015     DOI: 10.1007/s10096-017-2911-1

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  28 in total

1.  Inappropriate medication use in older adults: does nitrofurantoin belong on the list for the reasons stated?

Authors:  Calvin M Kunin
Journal:  Arch Intern Med       Date:  2004 Aug 9-23

2.  Oral therapy of catheter-associated bacteriuria (CAB) in the era of antibiotic resistance: nitrofurantoin revisited.

Authors:  Burke A Cunha; Paul Schoch; Jean E Hage
Journal:  J Chemother       Date:  2012-04       Impact factor: 1.714

3.  Alternatives to carbapenems in ESBL-producing Escherichia coli infections.

Authors:  D Fournier; C Chirouze; J Leroy; P Cholley; D Talon; P Plésiat; X Bertrand
Journal:  Med Mal Infect       Date:  2013-02-19       Impact factor: 2.152

4.  Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates.

Authors:  G Bonkat; G Müller; O Braissant; R Frei; S Tschudin-Suter; M Rieken; S Wyler; T C Gasser; A Bachmann; A F Widmer
Journal:  World J Urol       Date:  2013-01-29       Impact factor: 4.226

5.  Serum versus urinary antimicrobial concentrations in cure of urinary-tract infections.

Authors:  T A Stamey; W R Fair; M M Timothy; M A Millar; G Mihara; Y C Lowery
Journal:  N Engl J Med       Date:  1974-11-28       Impact factor: 91.245

6.  Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Simon Auer; Alexandra Wojna; Markus Hell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

7.  Pharmacodynamic studies of nitrofurantoin against common uropathogens.

Authors:  P Komp Lindgren; O Klockars; C Malmberg; O Cars
Journal:  J Antimicrob Chemother       Date:  2014-12-15       Impact factor: 5.790

8.  Effectiveness of achievable urinary concentrations of tetracyclines against "tetracycline-resistant" pathogenic bacteria.

Authors:  D M Musher; J N Minuth; S B Thorsteinsson; T Holmes
Journal:  J Infect Dis       Date:  1975-05       Impact factor: 5.226

9.  Urinary tract infection caused by Enterococcus isolates: aetiology and antimicrobial resistance patterns.

Authors:  Qing-Yong Wang; Rong-Hai Li; Xiao-Hong Shang
Journal:  J Chemother       Date:  2014-05-18       Impact factor: 1.714

10.  Antimicrobial stewardship programs (ASPs): the devil is in the details.

Authors:  Cheston B Cunha; Christy A Varughese; Eleftherios Mylonakis
Journal:  Virulence       Date:  2013-02-04       Impact factor: 5.882

View more
  5 in total

1.  Acute uncomplicated cystitis: is antibiotic unavoidable?

Authors:  Ekaterina Kulchavenya
Journal:  Ther Adv Urol       Date:  2018-06-20

2.  Nitrofurantoin and Fosfomycin for Extended Spectrum Beta-lactamases Producing Escherichia coli and Klebsiella pneumoniae.

Authors:  Neeraj Kumar Tulara
Journal:  J Glob Infect Dis       Date:  2018 Jan-Mar

3.  Leveraging Antimicrobial Stewardship in the Emergency Department to Improve the Quality of Urinary Tract Infection Management and Outcomes.

Authors:  Sarah C J Jorgensen; Samantha L Yeung; Mira Zurayk; Jill Terry; Maureen Dunn; Paul Nieberg; Jean Pallares; Annie Wong-Beringer
Journal:  Open Forum Infect Dis       Date:  2018-05-02       Impact factor: 3.835

4.  Unraveling Mechanisms and Epidemic Characteristics of Nitrofurantoin Resistance in Uropathogenic Enterococcus faecium Clinical Isolates.

Authors:  Ying Zhang; Lingbo Wang; Cui Zhou; Yishuai Lin; Shixing Liu; Weiliang Zeng; Kaihang Yu; Tieli Zhou; Jianming Cao
Journal:  Infect Drug Resist       Date:  2021-04-22       Impact factor: 4.003

5.  Effectiveness of extended- versus normal-release nitrofurantoin for cystitis: an instrumental variable analysis.

Authors:  Thijs Ten Doesschate; Rolf H H Groenwold; Marc J M Bonten; Cornelis H van Werkhoven
Journal:  J Antimicrob Chemother       Date:  2019-11-01       Impact factor: 5.790

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.